VBI Vaccines, Inc. (VBIV) Short Interest Up 163.4% in June
VBI Vaccines, Inc. (NASDAQ:VBIV) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,386,251 shares, a growth of 163.4% from the June 15th total of 526,262 shares. Based on an average daily trading volume, of 303,618 shares, the days-to-cover ratio is presently 4.6 days. Currently, 8.3% of the shares of the stock are short sold.
Hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its stake in VBI Vaccines by 66.5% in the first quarter. Bank of Montreal Can now owns 58,398 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 23,322 shares during the last quarter. EAM Investors LLC acquired a new stake in VBI Vaccines during the first quarter worth approximately $414,000. KCG Holdings Inc. purchased a new position in VBI Vaccines during the first quarter valued at $512,000. Finally, Goldman Sachs Group Inc. purchased a new position in VBI Vaccines during the first quarter valued at $383,000. Institutional investors and hedge funds own 29.18% of the company’s stock.
VBI Vaccines (NASDAQ VBIV) opened at 4.88 on Friday. VBI Vaccines has a 12 month low of $2.75 and a 12 month high of $6.60. The firm’s 50-day moving average is $4.30 and its 200 day moving average is $4.39. The firm’s market capitalization is $195.49 million.
Several research analysts have weighed in on the stock. Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Saturday. ValuEngine upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research report on Wednesday. TheStreet lowered shares of VBI Vaccines from a “c-” rating to a “d+” rating in a research report on Wednesday, May 31st. Finally, Noble Financial restated a “buy” rating on shares of VBI Vaccines in a research report on Monday, May 15th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. VBI Vaccines currently has a consensus rating of “Buy” and a consensus price target of $5.38.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.